Accelerated Stability Testing

Accelerated Stability Testing designates pharmaceutical stability studies conducted at elevated temperature and humidity conditions intentionally beyond normal storage requirements, enabling prediction of long-term product shelf life and identification of degradation pathways in compressed timeframes supporting development decisions and regulatory submissions before long-term data become available.

The pharmaceutical industry employs accelerated stability studies throughout development to guide formulation selection, packaging design, and storage condition determination before sufficient real-time data accumulate. ICH Q1A guidance specifies accelerated conditions including 40 degrees Celsius and 75% relative humidity for room-temperature products. Arrhenius modelling extrapolates accelerated degradation rates to predict real-time stability. Results support provisional shelf life assignment for clinical trial materials and early regulatory submissions. However, accelerated conditions may introduce degradation pathways absent under normal storage, requiring careful interpretation. As biologic stability prediction remains challenging due to complex degradation mechanisms, accelerated stability testing continues providing essential early guidance while requiring real-time data confirmation.